Oral ibandronic acid inferior to IV zoledronic acid for metastatic breast cancer to bone
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trialLancet Oncol. 2014 Jan;15(1):114-22. doi: 10.1016/S1470-2045(13)70539-4.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE